trending Market Intelligence /marketintelligence/en/news-insights/trending/9ep_wklibgofynexxrxrpa2 content esgSubNav
In This List

Inspyr Therapeutics' chief medical officer, directors resign

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Inspyr Therapeutics' chief medical officer, directors resign

Inspyr Therapeutics, Inc. said chief medical officer Ronald Shazer resigned from his position, effective Feb. 12.

Directors Peter Grebow and Richard Buller resigned from the company's board, effective Feb. 9.

The board resignations did not result from any disagreement with the company or matter relating to its operations, policies or practices, the Westlake Village, Calif.-based drug developer said in a Feb. 14 filing with the SEC.